STAAR Surgical Acquisition Facing Major Shareholder Opposition
STAAR Surgical's proposed acquisition by Alcon faces strong opposition from major shareholder Broadwood Partners, holding 27.5%, and former CEO David Bailey. Yunqi Capital Limited, with a 5.1% stake, has also spoken out against the offer. Broadwood Partners' recent presentation criticized the timing, negotiation process, and price of the acquisition, arguing that the deal undervalues STAAR Surgical and was rushed through without adequate consideration. David Bailey, who served as STAAR's CEO for about five months before the merger agreement with Alcon was executed in 2025, now opposes the takeover. Bailey's experience and insight into the company's operations add weight to Broadwood Partners' argument. Yunqi Capital Limited, holding 5.1% of STAAR's ordinary shares, has also expressed its disapproval of the offer. The acquisition of STAAR Surgical by Alcon is facing significant shareholder opposition, with major stakeholders including Broadwood Partners and former CEO David Bailey criticizing the deal. With such high-profile dissent, the future of the acquisition remains uncertain.
Read also:
- Trade Disputes Escalate: Trump Imposes Tariffs, India Retaliates; threatened boycott ranges from McDonald's, Coca-Cola to iPhones
- MIH Consortium Chooses BlackBerry for Next-Gen EV Platform
- Aquatech purchases Koch's Direct Lithium Extraction business, merging Li-ProTM DLE technology into the PEARLTM Technology Platform.
- North Carolina's Ocracoke Island: Highway Closed, Homes Collapse Due to Erosion
